133 related articles for article (PubMed ID: 38008447)
1. Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker.
Nagao S; Yabuuchi Y; Tanaka K; Morihisa Y; Kobayashi T; Akiyama S; Tanke G; Wada M; Morita S; Inoue S; Tei H; Yamashita D; Inokuma T
Intern Med; 2023 Nov; ():. PubMed ID: 38008447
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of gastric endoscopic submucosal dissection without using proton pump inhibitor injection: a propensity score analysis.
Fushimi S; Horikawa Y; Mizutamari H; Mimori N; Kato Y; Sato S
J Rural Med; 2020 Jul; 15(3):85-91. PubMed ID: 32704333
[No Abstract] [Full Text] [Related]
3. Clinical Impact of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker for Predicting the Curability of Endoscopic Resection in Ulcerative Early Gastric Cancer.
Uno K; Shimura T; Inaguma S; Kuroyanagi K; Nishigaki R; Kanno T; Sasaki M; Fukusada S; Sugimura N; Mizuno Y; Nukui T; Kojima Y; Tanaka M; Ozeki K; Kubota E; Takahashi S; Kataoka H
Digestion; 2024; 105(3):192-200. PubMed ID: 38310859
[TBL] [Abstract][Full Text] [Related]
4. Potassium-competitive acid blocker-associated gastric mucosal lesions.
Kubo K; Kimura N; Kato M
Clin Endosc; 2024 Feb; ():. PubMed ID: 38419167
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of proton pump inhibitors and potassium competitive acid blockers against post-gastric endoscopic submucosal dissection bleeding: a single-center, propensity score-matched analysis.
Toya Y; Endo M; Sugai K; Yamada S; Oizumi T; Morishita T; Akasaka R; Yanai S; Nakamura S; Eizuka M; Uesugi N; Sugai T; Matsumoto T
Scand J Gastroenterol; 2021 Feb; 56(2):199-204. PubMed ID: 33332216
[TBL] [Abstract][Full Text] [Related]
6. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
7. Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan.
Okamoto M; Wakunami Y; Hashimoto K
Intern Med; 2022 Jan; 61(1):119-122. PubMed ID: 34176835
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
Horikawa Y; Mizutamari H; Mimori N; Kato Y; Fushimi S; Sato S; Okubo S
Scand J Gastroenterol; 2018 Feb; 53(2):243-251. PubMed ID: 29214885
[TBL] [Abstract][Full Text] [Related]
9. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
10. The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease.
Kawaguchi K; Yashima K; Ikebuchi Y; Yoshida A; Kuwamoto S; Isomoto H
Intern Med; 2022 Sep; 61(17):2587-2592. PubMed ID: 35135919
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
12. [Potassium-competitive acid blocker].
Haruma K; Suehiro M; Kawamoto H; Manabe N
Nihon Rinsho; 2016 Aug; 74(8):1311-1315. PubMed ID: 30562434
[TBL] [Abstract][Full Text] [Related]
13. A rare case of an enterochromaffin-like neuroendocrine tumor associated with parietal cell dysfunction treated using endoscopic submucosal dissection.
Shiroma S; Higuchi K; Ota H; Umeno J; Ishioka M; Hirasawa T; Kuba H; Ono T; Uchima R; Nagamura R
Clin J Gastroenterol; 2022 Dec; 15(6):1041-1047. PubMed ID: 36125703
[TBL] [Abstract][Full Text] [Related]
14. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
15. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.
Li QL; Zhang YQ; Chen WF; Xu MD; Zhong YS; Ma LL; Qin WZ; Hu JW; Cai MY; Yao LQ; Zhou PH
World J Gastroenterol; 2012 Oct; 18(40):5799-806. PubMed ID: 23155323
[TBL] [Abstract][Full Text] [Related]
17. Morphological change of foveolar-type gastric adenocarcinoma after proton pump inhibitor discontinuation in a short time period: A case report.
Igarashi S; Hanabata N; Furusawa K; Suto S; Satake M; Shimaya K; Kanazawa K; Numao H; Munakata M; Kurotaki H; Sakuraba H; Yoshida S
DEN Open; 2024 Apr; 4(1):e293. PubMed ID: 37663228
[TBL] [Abstract][Full Text] [Related]
18. Proton Pump Inhibitor-Related Gastric Mucosal Changes.
Kim GH
Gut Liver; 2021 Sep; 15(5):646-652. PubMed ID: 32327613
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy of pharmacological therapies for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and network meta-analysis.
Gao H; Li L; Zhang C; Tu J; Geng X; Wang J; Zhou X; Jing J; Pan W
Expert Rev Gastroenterol Hepatol; 2020 Mar; 14(3):207-220. PubMed ID: 32063071
[No Abstract] [Full Text] [Related]
20. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
Simadibrata DM; Syam AF; Lee YY
J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
